News - Page 39 - Psychedelic Alpha

Read more about the article MIND CURE HEALTH INC. ANNOUNCES CLOSING OF THE FIRST TRANCHE OF LNG ENERGY GROUP’S SUBSCRIPTION RECEIPT FINANCING

MIND CURE HEALTH INC. ANNOUNCES CLOSING OF THE FIRST TRANCHE OF LNG ENERGY GROUP’S SUBSCRIPTION RECEIPT FINANCING

Post published:June 9, 2023
Post category:Press Release

Read more about the article MIND CURE AND LNG ENERGY GROUP PROVIDE UPDATE ON PREVIOUSLY ANNOUNCED BUSINESS COMBINATION TRANSACTION

MIND CURE AND LNG ENERGY GROUP PROVIDE UPDATE ON PREVIOUSLY ANNOUNCED BUSINESS COMBINATION TRANSACTION

Post published:June 9, 2023
Post category:Press Release

Read more about the article BetterLife Continues Progress on BETR-001 IND-Enabling Studies

BetterLife Continues Progress on BETR-001 IND-Enabling Studies

Post published:June 8, 2023
Post category:Press Release

Read more about the article Numinus to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

Numinus to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

Post published:June 8, 2023
Post category:Press Release

Read more about the article COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office

COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office

Post published:June 6, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Post published:June 6, 2023
Post category:Press Release

Read more about the article Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120

Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120

Post published:June 5, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Post published:June 5, 2023
Post category:Press Release

Read more about the article Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Post published:June 2, 2023
Post category:Press Release

Read more about the article Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Post published:June 2, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.